ADMA Biologics Inc $ADMA Stock Position Lessened by Creative Planning

Creative Planning reduced its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 10.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,009 shares of the biotechnology company’s stock after selling 8,648 shares during the quarter. Creative Planning’s holdings in ADMA Biologics were worth $1,366,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Envestnet Asset Management Inc. increased its stake in ADMA Biologics by 14.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 68,686 shares of the biotechnology company’s stock valued at $1,363,000 after buying an additional 8,682 shares during the period. Allianz Asset Management GmbH bought a new position in shares of ADMA Biologics in the first quarter valued at approximately $320,000. Cetera Investment Advisers increased its stake in shares of ADMA Biologics by 1.3% during the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock valued at $1,002,000 after acquiring an additional 670 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ADMA Biologics by 1.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company’s stock worth $1,323,000 after purchasing an additional 711 shares in the last quarter. Finally, LPL Financial LLC raised its holdings in ADMA Biologics by 84.7% during the first quarter. LPL Financial LLC now owns 110,253 shares of the biotechnology company’s stock worth $2,187,000 after purchasing an additional 50,565 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA opened at $19.12 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The firm’s 50 day moving average is $15.56 and its 200-day moving average is $17.30. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The stock has a market capitalization of $4.55 billion, a P/E ratio of 22.23 and a beta of 0.40.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.15 earnings per share. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $28.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.